166 related articles for article (PubMed ID: 34088773)
21. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
22. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
23. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after
Völter F; Mittlmeier L; Gosewisch A; Brosch-Lenz J; Gildehaus FJ; Zacherl MJ; Beyer L; Stief CG; Holzgreve A; Rübenthaler J; Cyran CC; Böning G; Bartenstein P; Todica A; Ilhan H
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33802417
[TBL] [Abstract][Full Text] [Related]
24.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
25. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
26. Comparison of different methods for post-therapeutic dosimetry in [
Rosar F; Schön N; Bohnenberger H; Bartholomä M; Stemler T; Maus S; Khreish F; Ezziddin S; Schaefer-Schuler A
EJNMMI Phys; 2021 May; 8(1):40. PubMed ID: 33950333
[TBL] [Abstract][Full Text] [Related]
27. Radiation Dosimetry in
Jackson PA; Hofman MS; Hicks RJ; Scalzo M; Violet J
J Nucl Med; 2020 Jul; 61(7):1030-1036. PubMed ID: 31806772
[TBL] [Abstract][Full Text] [Related]
28. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
29.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
30. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
31. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
32. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
Özkan A; Uçar B; Seymen H; Yildiz Yarar Y; Falay FO; Demirkol MO
Clin Nucl Med; 2020 Apr; 45(4):288-291. PubMed ID: 32049721
[TBL] [Abstract][Full Text] [Related]
33. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
34. [
Mercolli L; Mingels C; Manzini G; Cumming P; Zeimpekis K; Xue S; Alberts I; Uehlinger D; Rominger A; Shi K; Afshar-Oromieh A
J Nucl Med; 2023 Oct; 64(10):1570-1573. PubMed ID: 37620052
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [
Ha S; O JH; Park C; Boo SH; Yoo IR; Moon HW; Chi DY; Lee JY
Korean J Radiol; 2024 Feb; 25(2):179-188. PubMed ID: 38288897
[TBL] [Abstract][Full Text] [Related]
36. The
Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
[TBL] [Abstract][Full Text] [Related]
37. Radiomics Analysis for
Kelk E; Ruuge P; Rohtla K; Poksi A; Kairemo K
Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33671761
[TBL] [Abstract][Full Text] [Related]
38. Renal outcomes of radioligand therapy: experience of
Gallyamov M; Meyrick D; Barley J; Lenzo N
Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
[TBL] [Abstract][Full Text] [Related]
39. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
40. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]